Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Exploratory Study of Signals for Asthma Drugs in Children, Using the EudraVigilance Database of Spontaneous Reports.

Baan EJ, de Smet VA, Hoeve CE, Pacurariu AC, Sturkenboom MCJM, de Jongste JC, Janssens HM, Verhamme KMC.

Drug Saf. 2019 Oct 15. doi: 10.1007/s40264-019-00870-x. [Epub ahead of print]

PMID:
31617080
2.

Airway disease on chest computed tomography of preschool children with cystic fibrosis is associated with school-age bronchiectasis.

Bouma NR, Janssens HM, Andrinopoulou ER, Tiddens HAWM.

Pediatr Pulmonol. 2019 Sep 9. doi: 10.1002/ppul.24498. [Epub ahead of print]

PMID:
31496137
3.

Controlled evaluation of a transition clinic for Dutch young people with cystic fibrosis.

Peeters MAC, Sattoe JNT, van Staa A, Versteeg SE, Heeres I, Rutjes NW, Janssens HM.

Pediatr Pulmonol. 2019 Nov;54(11):1811-1820. doi: 10.1002/ppul.24476. Epub 2019 Aug 19.

PMID:
31424181
4.

Pharmacokinetics and safety of tobramycin nebulization with the I-neb and PARI-LC Plus in children with cystic fibrosis: A randomized, crossover study.

van Velzen AJ, Uges JWF, Heijerman HGM, Arets BGM, Nuijsink M, van der Wiel-Kooij EC, van Maarseveen EM, van Zanten GA, Pullens B, Touw DJ, Janssens HM.

Br J Clin Pharmacol. 2019 Sep;85(9):1984-1993. doi: 10.1111/bcp.13988. Epub 2019 Jul 10.

5.

Oxidative stress and abnormal bioactive lipids in early cystic fibrosis lung disease.

Scholte BJ, Horati H, Veltman M, Vreeken RJ, Garratt LW, Tiddens HAWM, Janssens HM, Stick SM; Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF).

J Cyst Fibros. 2019 Apr 25. pii: S1569-1993(19)30071-2. doi: 10.1016/j.jcf.2019.04.011. [Epub ahead of print]

PMID:
31031161
6.

Rectal Organoids Enable Personalized Treatment of Cystic Fibrosis.

Berkers G, van Mourik P, Vonk AM, Kruisselbrink E, Dekkers JF, de Winter-de Groot KM, Arets HGM, Marck-van der Wilt REP, Dijkema JS, Vanderschuren MM, Houwen RHJ, Heijerman HGM, van de Graaf EA, Elias SG, Majoor CJ, Koppelman GH, Roukema J, Bakker M, Janssens HM, van der Meer R, Vries RGJ, Clevers HC, de Jonge HR, Beekman JM, van der Ent CK.

Cell Rep. 2019 Feb 12;26(7):1701-1708.e3. doi: 10.1016/j.celrep.2019.01.068.

7.

Antibiotic use in children with asthma: cohort study in UK and Dutch primary care databases.

Baan EJ, Janssens HM, Kerckaert T, Bindels PJE, de Jongste JC, Sturkenboom MCJM, Verhamme KMC.

BMJ Open. 2018 Nov 28;8(11):e022979. doi: 10.1136/bmjopen-2018-022979.

8.

Elastase Exocytosis by Airway Neutrophils Is Associated with Early Lung Damage in Children with Cystic Fibrosis.

Margaroli C, Garratt LW, Horati H, Dittrich AS, Rosenow T, Montgomery ST, Frey DL, Brown MR, Schultz C, Guglani L, Kicic A, Peng L, Scholte BJ, Mall MA, Janssens HM, Stick SM, Tirouvanziam R.

Am J Respir Crit Care Med. 2019 Apr 1;199(7):873-881. doi: 10.1164/rccm.201803-0442OC.

PMID:
30281324
9.

Myeloperoxidase oxidation of methionine associates with early cystic fibrosis lung disease.

Chandler JD, Margaroli C, Horati H, Kilgore MB, Veltman M, Liu HK, Taurone AJ, Peng L, Guglani L, Uppal K, Go YM, Tiddens HAWM, Scholte BJ, Tirouvanziam R, Jones DP, Janssens HM.

Eur Respir J. 2018 Oct 10;52(4). pii: 1801118. doi: 10.1183/13993003.01118-2018. Print 2018 Oct.

PMID:
30190273
10.

Stratifying infants with cystic fibrosis for disease severity using intestinal organoid swelling as a biomarker of CFTR function.

de Winter-de Groot KM, Janssens HM, van Uum RT, Dekkers JF, Berkers G, Vonk A, Kruisselbrink E, Oppelaar H, Vries R, Clevers H, Houwen RHJ, Escher JC, Elias SG, de Jonge HR, de Rijke YB, Tiddens HAWM, van der Ent CK, Beekman JM.

Eur Respir J. 2018 Sep 17;52(3). pii: 1702529. doi: 10.1183/13993003.02529-2017. Print 2018 Sep.

PMID:
30166324
11.

Newborn blood spot screening for cystic fibrosis with a four-step screening strategy in the Netherlands.

Dankert-Roelse JE, Bouva MJ, Jakobs BS, Janssens HM, de Winter-de Groot KM, Schönbeck Y, Gille JJP, Gulmans VAM, Verschoof-Puite RK, Schielen PCJI, Verkerk PH.

J Cyst Fibros. 2019 Jan;18(1):54-63. doi: 10.1016/j.jcf.2018.07.008. Epub 2018 Aug 23.

PMID:
30146269
12.

Determination of thiocyanate in exhaled breath condensate.

Chandler JD, Horati H, Walker DI, Pagliano E, Tirouvanziam R, Veltman M, Scholte BJ, Janssens HM, Go YM, Jones DP.

Free Radic Biol Med. 2018 Oct;126:334-340. doi: 10.1016/j.freeradbiomed.2018.08.012. Epub 2018 Aug 22.

13.

Comparison of ex vivo and in vitro intestinal cystic fibrosis models to measure CFTR-dependent ion channel activity.

Zomer-van Ommen DD, de Poel E, Kruisselbrink E, Oppelaar H, Vonk AM, Janssens HM, van der Ent CK, Hagemeijer MC, Beekman JM.

J Cyst Fibros. 2018 May;17(3):316-324. doi: 10.1016/j.jcf.2018.02.007. Epub 2018 Mar 13.

PMID:
29544685
14.

Brand and generic use of inhalation medication and frequency of switching in children and adults: A population-based cohort study.

Engelkes M, van Blijderveen JC, Overbeek JA, Kuiper J, Herings RCM, Sturkenboom MCJM, de Jongste JC, Verhamme KMC, Janssens HM.

J Asthma. 2018 Oct;55(10):1086-1094. doi: 10.1080/02770903.2017.1396468. Epub 2017 Nov 29.

PMID:
29185812
15.

Patient-specific modelling of regional tobramycin concentration levels in airways of patients with cystic fibrosis: can we dose once daily?

Bos AC, Mouton JW, van Westreenen M, Andrinopoulou ER, Janssens HM, Tiddens HAWM.

J Antimicrob Chemother. 2017 Dec 1;72(12):3435-3442. doi: 10.1093/jac/dkx293.

PMID:
29029057
16.

Concordance between upper and lower airway microbiota in infants with cystic fibrosis.

Prevaes SM, de Steenhuijsen Piters WA, de Winter-de Groot KM, Janssens HM, Tramper-Stranders GA, Chu ML, Tiddens HA, van Westreenen M, van der Ent CK, Sanders EA, Bogaert D.

Eur Respir J. 2017 Mar 29;49(3). pii: 1602235. doi: 10.1183/13993003.02235-2016. Print 2017 Mar.

17.

The fate of inhaled antibiotics after deposition in cystic fibrosis: How to get drug to the bug?

Bos AC, Passé KM, Mouton JW, Janssens HM, Tiddens HA.

J Cyst Fibros. 2017 Jan;16(1):13-23. doi: 10.1016/j.jcf.2016.10.001. Epub 2016 Oct 26. Review.

18.

Real life data on incidence and risk factors of severe asthma exacerbations in children in primary care.

Engelkes M, Janssens HM, de Ridder MA, Sturkenboom MC, de Jongste JC, Verhamme KM.

Respir Med. 2016 Oct;119:48-54. doi: 10.1016/j.rmed.2016.08.016. Epub 2016 Aug 23.

19.

β2-Adrenergic receptor agonists activate CFTR in intestinal organoids and subjects with cystic fibrosis.

Vijftigschild LA, Berkers G, Dekkers JF, Zomer-van Ommen DD, Matthes E, Kruisselbrink E, Vonk A, Hensen CE, Heida-Michel S, Geerdink M, Janssens HM, van de Graaf EA, Bronsveld I, de Winter-de Groot KM, Majoor CJ, Heijerman HG, de Jonge HR, Hanrahan JW, van der Ent CK, Beekman JM.

Eur Respir J. 2016 Sep;48(3):768-79. doi: 10.1183/13993003.01661-2015. Epub 2016 Jul 28.

20.

Functional Characterization of Cholera Toxin Inhibitors Using Human Intestinal Organoids.

Zomer-van Ommen DD, Pukin AV, Fu O, Quarles van Ufford LH, Janssens HM, Beekman JM, Pieters RJ.

J Med Chem. 2016 Jul 28;59(14):6968-72. doi: 10.1021/acs.jmedchem.6b00770. Epub 2016 Jul 7.

PMID:
27347611
21.

Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis.

Dekkers JF, Berkers G, Kruisselbrink E, Vonk A, de Jonge HR, Janssens HM, Bronsveld I, van de Graaf EA, Nieuwenhuis EE, Houwen RH, Vleggaar FP, Escher JC, de Rijke YB, Majoor CJ, Heijerman HG, de Winter-de Groot KM, Clevers H, van der Ent CK, Beekman JM.

Sci Transl Med. 2016 Jun 22;8(344):344ra84. doi: 10.1126/scitranslmed.aad8278.

PMID:
27334259
22.

e-Monitoring of Asthma Therapy to Improve Compliance in children (e-MATIC): a randomised controlled trial.

Vasbinder EC, Goossens LM, Rutten-van Mölken MP, de Winter BC, van Dijk L, Vulto AG, Blankman EI, Dahhan N, Veenstra-van Schie MT, Versteegh FG, Wolf BH, Janssens HM, van den Bemt PM.

Eur Respir J. 2016 Sep;48(3):758-67. doi: 10.1183/13993003.01698-2015. Epub 2016 May 26.

23.

Potentiator synergy in rectal organoids carrying S1251N, G551D, or F508del CFTR mutations.

Dekkers JF, Van Mourik P, Vonk AM, Kruisselbrink E, Berkers G, de Winter-de Groot KM, Janssens HM, Bronsveld I, van der Ent CK, de Jonge HR, Beekman JM.

J Cyst Fibros. 2016 Sep;15(5):568-78. doi: 10.1016/j.jcf.2016.04.007. Epub 2016 May 5.

24.

Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids.

Dekkers JF, Gogorza Gondra RA, Kruisselbrink E, Vonk AM, Janssens HM, de Winter-de Groot KM, van der Ent CK, Beekman JM.

Eur Respir J. 2016 Aug;48(2):451-8. doi: 10.1183/13993003.01192-2015. Epub 2016 Apr 21.

25.

Daily Observations of Nebuliser Use and Technique (DONUT) in children with cystic fibrosis.

Bos AC, Tiddens HA, Tong Minh K, Heeres I, Overweel-Uijterlinde JL, Kok AE, Andrinopoulou ER, Janssens HM.

J Cyst Fibros. 2016 Sep;15(5):645-51. doi: 10.1016/j.jcf.2016.03.005. Epub 2016 Mar 24.

26.

Prescription patterns, adherence and characteristics of non-adherence in children with asthma in primary care.

Engelkes M, Janssens HM, de Jongste JC, Sturkenboom MC, Verhamme KM.

Pediatr Allergy Immunol. 2016 Mar;27(2):201-8. doi: 10.1111/pai.12507. Epub 2015 Dec 21.

PMID:
26928754
27.

Pharmacokinetics and Tolerability of Once Daily Double Dose Tobramycin Inhalation in Cystic Fibrosis Using Controlled and Conventional Nebulization.

van Velzen AJ, Bos AC, Touw DJ, Tiddens HA, Heijerman HG, Janssens HM.

J Aerosol Med Pulm Drug Deliv. 2016 Jun;29(3):273-80. doi: 10.1089/jamp.2015.1259. Epub 2015 Dec 30.

PMID:
26716357
28.

Optimization and Dose Estimation of Aerosol Delivery to Non-Human Primates.

MacLoughlin RJ, van Amerongen G, Fink JB, Janssens HM, Duprex WP, de Swart RL.

J Aerosol Med Pulm Drug Deliv. 2016 Jun;29(3):281-7. doi: 10.1089/jamp.2015.1250. Epub 2015 Dec 8.

PMID:
26646908
29.

rAAV-CFTRΔR Rescues the Cystic Fibrosis Phenotype in Human Intestinal Organoids and Cystic Fibrosis Mice.

Vidović D, Carlon MS, da Cunha MF, Dekkers JF, Hollenhorst MI, Bijvelds MJ, Ramalho AS, Van den Haute C, Ferrante M, Baekelandt V, Janssens HM, De Boeck K, Sermet-Gaudelus I, de Jonge HR, Gijsbers R, Beekman JM, Edelman A, Debyser Z.

Am J Respir Crit Care Med. 2016 Feb 1;193(3):288-98. doi: 10.1164/rccm.201505-0914OC.

PMID:
26509335
30.

Development of the Nasopharyngeal Microbiota in Infants with Cystic Fibrosis.

Prevaes SM, de Winter-de Groot KM, Janssens HM, de Steenhuijsen Piters WA, Tramper-Stranders GA, Wyllie AL, Hasrat R, Tiddens HA, van Westreenen M, van der Ent CK, Sanders EA, Bogaert D.

Am J Respir Crit Care Med. 2016 Mar 1;193(5):504-15. doi: 10.1164/rccm.201509-1759OC.

PMID:
26492486
31.

Limited premature termination codon suppression by read-through agents in cystic fibrosis intestinal organoids.

Zomer-van Ommen DD, Vijftigschild LA, Kruisselbrink E, Vonk AM, Dekkers JF, Janssens HM, de Winter-de Groot KM, van der Ent CK, Beekman JM.

J Cyst Fibros. 2016 Mar;15(2):158-62. doi: 10.1016/j.jcf.2015.07.007. Epub 2015 Aug 5.

32.

Time trends in the incidence, prevalence and age at diagnosis of asthma in children.

Engelkes M, Janssens HM, de Ridder MA, de Jongste JC, Sturkenboom MC, Verhamme KM.

Pediatr Allergy Immunol. 2015 Jun;26(4):367-74. doi: 10.1111/pai.12376.

PMID:
25827225
33.

Patient-specific modeling of regional antibiotic concentration levels in airways of patients with cystic fibrosis: are we dosing high enough?

Bos AC, van Holsbeke C, de Backer JW, van Westreenen M, Janssens HM, Vos WG, Tiddens HA.

PLoS One. 2015 Mar 3;10(3):e0118454. doi: 10.1371/journal.pone.0118454. eCollection 2015.

34.

A bioassay using intestinal organoids to measure CFTR modulators in human plasma.

Dekkers R, Vijftigschild LA, Vonk AM, Kruisselbrink E, de Winter-de Groot KM, Janssens HM, van der Ent CK, Beekman JM.

J Cyst Fibros. 2015 Mar;14(2):178-81. doi: 10.1016/j.jcf.2014.10.007. Epub 2014 Nov 6.

35.

Inhaled antibiotics: dry or wet?

Tiddens HA, Bos AC, Mouton JW, Devadason S, Janssens HM.

Eur Respir J. 2014 Nov;44(5):1308-18. doi: 10.1183/09031936.00090314. Epub 2014 Oct 16. Review.

36.

Medication adherence and the risk of severe asthma exacerbations: a systematic review.

Engelkes M, Janssens HM, de Jongste JC, Sturkenboom MC, Verhamme KM.

Eur Respir J. 2015 Feb;45(2):396-407. doi: 10.1183/09031936.00075614. Epub 2014 Oct 16. Review.

37.

An instrumented valved holding chamber with facemask to measure application forces and flow in young asthmatic children.

Minh KT, von Hollen D, von Königslöw AJ, Nikander K, Janssens HM.

J Aerosol Med Pulm Drug Deliv. 2014 Aug;27 Suppl 1:S55-62. doi: 10.1089/jamp.2014.1129.

PMID:
25054482
38.

A functional CFTR assay using primary cystic fibrosis intestinal organoids.

Dekkers JF, Wiegerinck CL, de Jonge HR, Bronsveld I, Janssens HM, de Winter-de Groot KM, Brandsma AM, de Jong NW, Bijvelds MJ, Scholte BJ, Nieuwenhuis EE, van den Brink S, Clevers H, van der Ent CK, Middendorp S, Beekman JM.

Nat Med. 2013 Jul;19(7):939-45. doi: 10.1038/nm.3201. Epub 2013 Jun 2.

PMID:
23727931
39.

Automatic generation of case-detection algorithms to identify children with asthma from large electronic health record databases.

Afzal Z, Engelkes M, Verhamme KM, Janssens HM, Sturkenboom MC, Kors JA, Schuemie MJ.

Pharmacoepidemiol Drug Saf. 2013 Aug;22(8):826-33. doi: 10.1002/pds.3438. Epub 2013 Apr 17.

PMID:
23592573
40.

e-Monitoring of Asthma Therapy to Improve Compliance in children using a real-time medication monitoring system (RTMM): the e-MATIC study protocol.

Vasbinder EC, Janssens HM, Rutten-van Mölken MP, van Dijk L, de Winter BC, de Groot RC, Vulto AG, van den Bemt PM; e-MATIC Study Group.

BMC Med Inform Decis Mak. 2013 Mar 21;13:38. doi: 10.1186/1472-6947-13-38.

41.

Diagnosis of invasive pulmonary aspergillosis in children with bronchoalveolar lavage galactomannan.

de Mol M, de Jongste JC, van Westreenen M, Merkus PJ, de Vries AH, Hop WC, Warris A, Janssens HM.

Pediatr Pulmonol. 2013 Aug;48(8):789-96. doi: 10.1002/ppul.22670. Epub 2012 Sep 4.

PMID:
22949309
42.

[Guideline "Treatment of asthma in children": 3 controversial approaches to treatment].

Rottier BL, Janssens HM, de Jongste JC, Brouwer ML, Vrijlandt EJ, Boluyt N.

Ned Tijdschr Geneeskd. 2012;156(23):A4389. Review. Dutch.

PMID:
22727227
43.

What the pulmonary specialist should know about the new inhalation therapies.

Laube BL, Janssens HM, de Jongh FH, Devadason SG, Dhand R, Diot P, Everard ML, Horvath I, Navalesi P, Voshaar T, Chrystyn H; European Respiratory Society; International Society for Aerosols in Medicine.

Eur Respir J. 2011 Jun;37(6):1308-31. doi: 10.1183/09031936.00166410. Epub 2011 Feb 10.

44.

Facemasks and aerosol delivery by metered dose inhaler-valved holding chamber in young children: a tight seal makes the difference.

Janssens HM, Tiddens HA.

J Aerosol Med. 2007;20 Suppl 1:S59-63; discussion S63-5. Review.

PMID:
17411407
45.

Aerosol therapy: the special needs of young children.

Janssens HM, Tiddens HA.

Paediatr Respir Rev. 2006;7 Suppl 1:S83-5. Epub 2006 Jun 5. Review.

PMID:
16798606
46.

In vitro determination of the optimal particle size for nebulized aerosol delivery to infants.

Schüepp KG, Jauernig J, Janssens HM, Tiddens HA, Straub DA, Stangl R, Keller M, Wildhaber JH.

J Aerosol Med. 2005 Summer;18(2):225-35.

PMID:
15966777
47.

Determining factors of aerosol deposition for four pMDI-spacer combinations in an infant upper airway model.

Janssens HM, Krijgsman A, Verbraak TF, Hop WC, de Jongste JC, Tiddens HA.

J Aerosol Med. 2004 Spring;17(1):51-61.

PMID:
15120013
48.

Aerosol therapy and the fighting toddler: is administration during sleep an alternative?

Janssens HM, van der Wiel EC, Verbraak AF, de Jongste JC, Merkus PJ, Tiddens HA.

J Aerosol Med. 2003 Winter;16(4):395-400.

PMID:
14977430
49.

Extra-fine particles improve lung delivery of inhaled steroids in infants: a study in an upper airway model.

Janssens HM, De Jongste JC, Hop WC, Tiddens HA.

Chest. 2003 Jun;123(6):2083-8.

PMID:
12796192
50.

Effectiveness of pharmacotherapy in asthmatic preschool children.

de Jongste JC, Janssens HM, Van der Wouden J.

Allergy. 2002;57 Suppl 74:42-7. Review.

PMID:
12371912

Supplemental Content

Loading ...
Support Center